Holen Sie sich die Stockscreener-App
17.30
0.87%
0.15
Handel nachbörslich:
17.28
-0.02
-0.12%
Schlusskurs vom Vortag:
$17.15
Offen:
$17.25
24-Stunden-Volumen:
4.15M
Relative Volume:
1.29
Marktkapitalisierung:
$2.47B
Einnahmen:
$62.38M
Nettoeinkommen (Verlust:
$-101.59M
KGV:
-20.01
EPS:
-0.8644
Netto-Cashflow:
$-139.93M
1W Leistung:
+2.06%
1M Leistung:
+34.11%
6M Leistung:
+164.93%
1J Leistung:
+830.11%
1-Tages-Spanne:
$16.77
$17.58
1-Wochen-Bereich:
$16.11
$17.58
52-Wochen-Spanne:
$1.03
$17.63
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
17.30 | 2.47B | 62.38M | -101.59M | -139.93M | -0.8644 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Tango Therapeutics (TNGX) Soars 52% on Buy Reco - MSN
Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings - finance.yahoo.com
Tango Therapeutics Inc (TNGX) Stock News & Articles - 24/7 Wall St.
Mizuho Forecasts Strong Price Appreciation for Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Stifel raises Tango Therapeutics stock price target on PRMT5 data By Investing.com - Investing.com Nigeria
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) - Bitget
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Adam Crystal Sells 20,251 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Stifel raises Tango Therapeutics stock price target on PRMT5 data - Investing.com India
Insider sale: Tango Therapeutics (TNGX) R&D president sells shares - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St.
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration? - Yahoo Finance
Tango Therapeutics (NASDAQ:TNGX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Barclays Global Healthcare Conference - marketscreener.com
Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple - finance.yahoo.com
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), McKesson (MCK) and Cybin (HELP) - The Globe and Mail
Tango Therapeutics (NASDAQ:TNGX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Blue Owl Capital Holdings LP Sells 695,000 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cooper Co (COO) and CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Tango Therapeutics (TNGX) Q4 Revenue Collapse To US$0 Reinforces Bearish Volatility Narrative - simplywall.st
New hire gets options on 367,500 Tango Therapeutics shares - Stock Titan
Tango Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics (NASDAQ:TNGX) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Wedbush Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Tango Therapeutics Stock Surges 36% on Strong Q4 Results, Pipeline Momentum and Cash Runway Extension - International Business Times Australia
Tango Therapeutics (NASDAQ:TNGX) Given New $20.00 Price Target at Guggenheim - MarketBeat
Tango Therapeutics (TNGX) Q4 Loss Narrows to $0.29/Share vs $0.33 Estimate; Shares Surge 23% - AlphaStreet
Tango Therapeutics (NASDAQ:TNGX) Price Target Raised to $27.00 at HC Wainwright - MarketBeat
4 Analysts Have This To Say About Tango Therapeutics - Benzinga
Rafferty Asset Management LLC Purchases New Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics (TNGX) hits all-time high as analyst turns bullish - MSN
Stocks to Watch Right Now: EcoPetrol, Credo, Sable Offshore, and More - Insider Monkey
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish - Insider Monkey
Jefferies raises Tango Therapeutics stock price target on RAS deal By Investing.com - Investing.com UK
Jefferies raises Tango Therapeutics stock price target on RAS deal - Investing.com Nigeria
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
Erasca and Tango Therapeutics Partner to Study ERAS-007 and Vopimetostat Combination for MTAP-Deleted Cancers - geneonline.com
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango Therapeutics stock hits 52-week high at $13.66 By Investing.com - Investing.com Australia
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Tango Therapeutics stock hits 52-week high at $13.66 - Investing.com Nigeria
Tango Therapeutics Shares Rise After Q4 Loss Narrows - marketscreener.com
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):